Events

Jefferies London Healthcare Conference 2022 /w Nick Keher

Nick Keher, BenevolentAI’s CFO, is scheduled to present at 10.20 AM on Thursday 17th November at the upcoming Jefferies London Healthcare Conference.

The presentation will be live-streamed on the following link, and a recording will be made available on the Investor Portal of BenevolentAI’s website.

BenevolentAI’s management, investor relations and business development team will be attending and available throughout the conference for meetings. Connect with these teams using the following details:


Nick Keher

Chief Financial Officer

Nick Keher joined as CFO in March 2022 having previously been CFO of Clinigen, a UK AIM listed pharmaceutical and pharma services company with over £450m of revenue. Nick spent eight years as an equity analyst covering the European healthcare space, first at Investec and then at RBC where he was Head of RBC’s European healthcare equity research team. Nick began his career as a registered pharmacist at Lloyd’s Pharmacy, before joining GSK in its finance function.

More Posts

You Might Also Like

News
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
Blog
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
News
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
News
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022
News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
News
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022